INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36001, 15840, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36002, 15920, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36003, 17659, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36004, 17660, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36005, 21258, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36006, 21259, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36007, 29061, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36008, 29287, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36009, 29288, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36010, 29289, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36011, 2058, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36012, 2101, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36013, 2103, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36014, 2127, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36015, 2128, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36016, 2130, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36017, 2131, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36018, 2132, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36019, 2133, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36020, 2137, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36021, 3688, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36022, 3689, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36023, 15840, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36024, 15920, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36025, 17659, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36026, 17660, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36027, 21258, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36028, 21259, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36029, 29061, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36030, 29287, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36031, 29288, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36032, 29289, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36033, 2058, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36034, 2101, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36035, 2103, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36036, 2127, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36037, 2128, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36038, 2130, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36039, 2131, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36040, 2132, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36041, 2133, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36042, 2137, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36043, 3688, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36044, 3689, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36045, 15840, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36046, 15920, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36047, 17659, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36048, 17660, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36049, 21258, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36050, 21259, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36051, 29061, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36052, 29287, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36053, 29288, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36054, 29289, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36055, 2058, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36056, 2101, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36057, 2103, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36058, 2127, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36059, 2128, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36060, 2130, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36061, 2131, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36062, 2132, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36063, 2133, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36064, 2137, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36065, 3688, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36066, 3689, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36067, 15840, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36068, 15920, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36069, 17659, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36070, 17660, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36071, 21258, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36072, 21259, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36073, 29061, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36074, 29287, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36075, 29288, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36076, 29289, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36077, 2058, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36078, 2101, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36079, 2103, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36080, 2127, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36081, 2128, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36082, 2130, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36083, 2131, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36084, 2132, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36085, 2133, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36086, 2137, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36087, 3688, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36088, 3689, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36089, 15840, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36090, 15920, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36091, 17659, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36092, 17660, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36093, 21258, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36094, 21259, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36095, 29061, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36096, 29287, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36097, 29288, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36098, 29289, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36099, 2058, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36100, 2101, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36101, 2103, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36102, 2127, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36103, 2128, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36104, 2130, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36105, 2131, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36106, 2132, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36107, 2133, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36108, 2137, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36109, 3688, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36110, 3689, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36111, 15840, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36112, 15920, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36113, 17659, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36114, 17660, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36115, 21258, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36116, 21259, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36117, 29061, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36118, 29287, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36119, 29288, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36120, 29289, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36121, 2058, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36122, 2101, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36123, 2103, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36124, 2127, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36125, 2128, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36126, 2130, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36127, 2131, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36128, 2132, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36129, 2133, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36130, 2137, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36131, 3688, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36132, 3689, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36133, 15840, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36134, 15920, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36135, 17659, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36136, 17660, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36137, 21258, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36138, 21259, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36139, 29061, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36140, 29287, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36141, 29288, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36142, 29289, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'Dupont AG "Carvedilol and the kidney." Clin Investig 70 Suppl 1 (1992):  s127-31|Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M "Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan." Drugs 36 Suppl 6 (1988):  129-35|Kramer BK, Ress KM, Erley CM, Risler T "Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure." Eur J Clin Pharmacol 43 (1992):  85-8|Dupont AG "Effects of carvedilol on renal function." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s96-100|Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, Mizuno Y, Fukiyama K, Fujishima M, Yoshimura M "Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial." Eur J Clin Pharmacol 38 Suppl 2 (1990):  s158-63|Tomita K, Marumo F "Effect of long-term carvedilol therapy on renal function in essential hypertension." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s97-101|Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y "Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients." J Cardiovasc Pharmacol 19 Suppl 1 (1992):  s102-7|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36143, 2058, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36144, 2101, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36145, 2103, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36146, 2127, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36147, 2128, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36148, 2130, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36149, 2131, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36150, 2132, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36151, 2133, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36152, 2137, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36153, 3688, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36154, 3689, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36155, 15840, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36156, 15920, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36157, 17659, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36158, 17660, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36159, 21258, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36160, 21259, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36161, 29061, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36162, 29287, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36163, 29288, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36164, 29289, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36165, 0, 'Carteolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36166, 0, 'Carteolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36167, 0, 'Carteolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36168, 0, 'Carteolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36169, 0, 'Carteolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36170, 0, 'Carteolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36171, 0, 'Carteolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36172, 0, 'Carteolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36173, 0, 'Carteolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36174, 23203, 'Carisoprodol', 'Porphyrias', 'The use of carisoprodol is contraindicated in patients with acute intermittent porphyria.  Carisoprodol is partially metabolized to the pharmacologically active meprobamate, which has been reported to precipitate acute attacks of porphyria in susceptible patients.', '3', '"Product Information. Soma (carisoprodol)." Meda Pharmaceuticals  (2001):|Hazen PG "Pseudoporphyria in a patient receiving carisoprodol/aspirin therapy." J Am Acad Dermatol 31 (1994):  500|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36175, 23203, 'Carisoprodol', 'Substance-Related Disorders', 'Carisoprodol is partially metabolized to meprobamate, a pharmacologically active agent with known addictive potential.  According to the manufacturer, abrupt cessation of carisoprodol 100 mg/kg/day (approximately 5 times the recommended daily adult dosage) was associated with mild withdrawal symptoms such as abdominal cramps, insomnia, headache, nausea and chills in some study subjects.  In clinical use, psychological dependence and abuse have been rare.  Nevertheless, therapy with carisoprodol should be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'Elder NC "Abuse of skeletal muscle relaxants." Am Fam Physician 44 (1991):  1223-6|Luehr JG, Meyerle KA, Larson EW "Mail-order (veterinary) drug dependence." JAMA 263 (1990):  657|Morse RM, Chua L "Carisoprodol dependence: a case report." Am J Drug Alcohol Abuse 5 (1978):  527-30|"Product Information. Soma (carisoprodol)." Meda Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36176, 23203, 'Carisoprodol', 'Liver Diseases', 'Carisoprodol is primarily converted in the liver to several metabolites, one of which (meprobamate) is pharmacologically active.  The metabolites and a small amount of the parent drug are excreted in the urine.  Patients with impaired renal and/or hepatic function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with carisoprodol should be administered cautiously in such patients.', '2', '"Product Information. Soma (carisoprodol)." Meda Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36177, 1538, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36178, 1539, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36179, 1540, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36180, 1541, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36181, 2205, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36182, 2206, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36183, 2235, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36184, 3185, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36185, 3189, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36186, 3190, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36187, 3916, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36188, 3919, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36189, 3920, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36190, 3922, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36191, 5491, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36192, 6354, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36193, 6356, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36194, 7506, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36195, 7508, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36196, 15999, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36197, 16000, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36198, 16011, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36199, 16110, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36200, 16111, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36201, 16954, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36202, 16956, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36203, 16957, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36204, 16960, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36205, 17964, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36206, 17972, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36207, 17976, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36208, 20671, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36209, 20672, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36210, 20673, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36211, 20675, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36212, 22012, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36213, 22469, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36214, 22470, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36215, 26366, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36216, 26367, 'Cefadroxil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36217, 1538, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36218, 1539, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36219, 1540, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36220, 1541, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36221, 2205, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36222, 2206, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36223, 2235, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36224, 3185, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36225, 3189, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36226, 3190, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36227, 3916, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36228, 3919, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36229, 3920, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36230, 3922, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36231, 5491, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36232, 6354, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36233, 6356, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36234, 7506, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36235, 7508, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36236, 15999, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36237, 16000, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36238, 16011, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36239, 16110, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36240, 16111, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36241, 16954, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36242, 16956, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36243, 16957, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36244, 16960, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36245, 17964, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36246, 17972, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36247, 17976, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36248, 20671, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36249, 20672, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36250, 20673, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36251, 20675, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36252, 22012, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36253, 22469, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36254, 22470, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36255, 26366, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36256, 26367, 'Cefadroxil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36257, 1538, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36258, 1539, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36259, 1540, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36260, 1541, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36261, 2205, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36262, 2206, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36263, 2235, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36264, 3185, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36265, 3189, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36266, 3190, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36267, 3916, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36268, 3919, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36269, 3920, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36270, 3922, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36271, 5491, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36272, 6354, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36273, 6356, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36274, 7506, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36275, 7508, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36276, 15999, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36277, 16000, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36278, 16011, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36279, 16110, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36280, 16111, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36281, 16954, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36282, 16956, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36283, 16957, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36284, 16960, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36285, 17964, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36286, 17972, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36287, 17976, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36288, 20671, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36289, 20672, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36290, 20673, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36291, 20675, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36292, 22012, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36293, 22469, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36294, 22470, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36295, 26366, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36296, 26367, 'Cefadroxil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36297, 1538, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36298, 1539, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36299, 1540, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36300, 1541, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36301, 2205, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36302, 2206, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36303, 2235, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36304, 3185, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36305, 3189, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36306, 3190, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36307, 3916, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36308, 3919, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36309, 3920, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36310, 3922, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36311, 5491, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36312, 6354, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36313, 6356, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36314, 7506, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36315, 7508, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36316, 15999, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36317, 16000, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36318, 16011, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36319, 16110, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36320, 16111, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36321, 16954, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36322, 16956, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36323, 16957, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36324, 16960, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36325, 17964, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36326, 17972, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36327, 17976, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36328, 20671, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36329, 20672, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36330, 20673, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36331, 20675, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36332, 22012, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36333, 22469, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36334, 22470, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36335, 26366, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36336, 26367, 'Cefadroxil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36337, 0, 'Carmustine', 'Pulmonary Fibrosis', 'Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported during carmustine therapy.  Toxicity has occurred within nine days of initiation of therapy at doses usually > 1400 mg/m2.  However, cases of delayed onset pulmonary fibrosis occurring up to 17 years after treatment have also been reported.  Late reduction in pulmonary function, progressive fibrosis, and death have been noted.  Risk factors include past history of lung disease and duration of treatment.  Therapy with carmustine should be administered cautiously in patients with a history of pulmonary disease.  Pulmonary function studies prior to and during therapy are recommended.', '3', 'Sweet DL "Pulmonary effects of carmustine (bischloroethylnitrosourea, BCNU)." Ann Intern Med 91 (1979):  132-3|Weiss RB, Muggia FM "Pulmonary effects of carmustine (bischloroethylnitrosourea, BCNU)." Ann Intern Med 91 (1979):  131-2|O''Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA "Late carmustine lung fibrosis. Age at treatment may influence severity and survival." Chest 107 (1995):  1355-7|Lena H, Desrues B, Le Coz A, Quinquenel ML, Delaval P "Severe diffuse interstitial pneumonitis induced by carmustine (BCNU)." Chest 105 (1994):  1602-3|Patten GA, Billi JE, Rotman HH "Rapidly progressive, fatal pulmonary fibrosis induced by carmustine." JAMA 244 (1980):  687-8|Weinstein AS, Diener-West M, Nelson DF, Pakuris E "Pulmonary toxicity of carmustine in patients treated for malignant glioma." Cancer Treat Rep 70 (1986):  943-6|"Product Information. BiCNU (carmustine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36338, 0, 'Carmustine', 'Infections', 'Nitrosoureas can induce delayed myelosuppression.  The use of nitrosoureas may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with nitrosoureas.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. CeeNU (lomustine)." Bristol-Myers Squibb  (2001):|"Product Information. BiCNU (carmustine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36339, 0, 'Carmustine', 'Bone Marrow Failure Disorders', 'Nitrosoureas induce delayed bone marrow suppression that is cumulative and dose-related.  Thrombocytopenia is usually more severe than leukopenia.  Anemia occurs less frequently and is less severe.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, bleeding or symptoms of anemia.  Therapy with nitrosoureas should be administered cautiously in patients with bone marrow suppression.  Blood counts should be monitored at least six weeks after a dose and dosage adjustments made based on the nadir blood counts of the previous dose.', '3', '"Product Information. CeeNU (lomustine)." Bristol-Myers Squibb  (2001):|"Product Information. BiCNU (carmustine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36340, 0, 'Carmustine', 'Kidney Diseases', 'Renal abnormalities such as azotemia, and progressive decline in renal function have been reported after prolonged therapy with large doses of carmustine and lomustine.  Lower total doses have also resulted in kidney damage.  Therapy with carmustine or lomustine should be administered cautiously in patients with a history of or predisposition to renal dysfunction.  Clinical monitoring of renal function is recommended.', '2', 'Seffart G ed. "Drug Dosage in Renal Insufficiency." Dordrecht, South Holland,   : Kluwer Academic Publishers  (1991):|Ellis ME, Weiss RB, Kuperminc M "Nephrotoxicity of lomustine. A case report and literature review." Cancer Chemother Pharmacol 15 (1985):  174-5|Weiss RB, Poster DS "THE RENAL TOXICITY OF CANCER CHEMOTHERAPEUTIC AGENTS." Cancer Treat Rev 9 (1982):  37-561982|"Product Information. CeeNU (lomustine)." Bristol-Myers Squibb  (2001):|"Product Information. BiCNU (carmustine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36341, 0, 'Carmustine', 'Liver Diseases', 'A reversible increase in liver transaminase, alkaline phosphatase, and bilirubin levels has been reported during therapy with nitrosoureas.  Therapy with nitrosoureas should be administered cautiously in patients with a history of or predisposition to compromised hepatic function.', '1', '"Product Information. CeeNU (lomustine)." Bristol-Myers Squibb  (2001):|"Product Information. BiCNU (carmustine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36342, 15928, 'Castor oil', 'Dehydration', 'The use of castor oil is contraindicated in patients with dehydration or electrolyte imbalance.  Castor oil is hydrolyzed to glycerol and ricinoleic acid within the small intestine.  Ricinoleic acid acts on the small intestine to reduce the net absorption of fluid and electrolytes.  This altered intestinal permeability caused by castor oil may produce dehydration and electrolyte imbalance.', '3', '"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36343, 15928, 'Castor oil', 'Intestinal Obstruction', 'The use of castor oil is contraindicated in patients with intestinal obstruction.  Fluid and electrolyte build up in the intestinal tract due to castor oil may exacerbate intestinal obstruction.', '3', '"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36344, 15928, 'Castor oil', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36345, 15928, 'Castor oil', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36346, 914, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36347, 915, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36348, 2030, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36349, 2033, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36350, 2034, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36351, 2035, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36352, 2038, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36353, 2426, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36354, 4281, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36355, 7813, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36356, 7814, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36357, 8768, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36358, 8769, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36359, 11228, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36360, 11232, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36361, 11234, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36362, 11236, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36363, 11237, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36364, 11512, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36365, 15804, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36366, 15805, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36367, 18431, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36368, 18432, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36369, 22416, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36370, 23465, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36371, 23476, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36372, 23477, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36373, 27980, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36374, 27981, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36375, 28279, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36376, 28280, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36377, 28282, 'Carbamazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36378, 914, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36379, 915, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36380, 2030, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36381, 2033, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36382, 2034, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36383, 2035, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36384, 2038, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36385, 2426, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36386, 4281, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36387, 7813, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36388, 7814, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36389, 8768, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36390, 8769, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36391, 11228, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36392, 11232, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36393, 11234, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36394, 11236, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36395, 11237, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36396, 11512, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36397, 15804, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36398, 15805, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36399, 18431, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36400, 18432, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36401, 22416, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36402, 23465, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36403, 23476, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36404, 23477, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36405, 27980, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36406, 27981, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36407, 28279, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36408, 28280, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36409, 28282, 'Carbamazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):|"Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36410, 914, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36411, 915, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36412, 2030, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36413, 2033, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36414, 2034, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36415, 2035, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36416, 2038, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36417, 2426, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36418, 4281, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36419, 7813, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36420, 7814, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36421, 8768, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36422, 8769, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36423, 11228, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36424, 11232, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36425, 11234, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36426, 11236, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36427, 11237, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36428, 11512, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36429, 15804, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36430, 15805, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36431, 18431, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36432, 18432, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36433, 22416, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36434, 23465, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36435, 23476, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36436, 23477, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36437, 27980, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36438, 27981, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36439, 28279, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36440, 28280, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36441, 28282, 'Carbamazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36442, 914, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36443, 915, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36444, 2030, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36445, 2033, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36446, 2034, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36447, 2035, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36448, 2038, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36449, 2426, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36450, 4281, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36451, 7813, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36452, 7814, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36453, 8768, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36454, 8769, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36455, 11228, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36456, 11232, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36457, 11234, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36458, 11236, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36459, 11237, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36460, 11512, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36461, 15804, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36462, 15805, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36463, 18431, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36464, 18432, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36465, 22416, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36466, 23465, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36467, 23476, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36468, 23477, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36469, 27980, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36470, 27981, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36471, 28279, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36472, 28280, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36473, 28282, 'Carbamazepine', 'Hematologic Diseases', 'The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis.  Carbamazepine should not be used in patients with history of bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.  Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely.  Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36474, 914, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36475, 915, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36476, 2030, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36477, 2033, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36478, 2034, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36479, 2035, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36480, 2038, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36481, 2426, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36482, 4281, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36483, 7813, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36484, 7814, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36485, 8768, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36486, 8769, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36487, 11228, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36488, 11232, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36489, 11234, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36490, 11236, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36491, 11237, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36492, 11512, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36493, 15804, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36494, 15805, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36495, 18431, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36496, 18432, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36497, 22416, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36498, 23465, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36499, 23476, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36500, 23477, 'Carbamazepine', 'Porphyrias, Hepatic', 'The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).  Acute attacks have been reported in such patients receiving carbamazepine therapy.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
